# CONTENTS

## ACKNOWLEDGMENTS  

## INTRODUCTION  

### PART A  LIFECYCLE MANAGEMENT BUSINESS ENVIRONMENT  

**1. Challenges Facing the Branded Drug Industry**  

1.1 Depleted NME Pipelines/Lower R&D Efficiency  
1.2 Higher Development Costs  
1.3 Safety Concerns  
1.4 Tougher Environment for Pricing, Reimbursement, and Listing  
1.5 Increased Competition  
1.6 Earlier Genericization  
1.7 Faster Sales Erosion Following Patent Expiry  
1.8 Poor Image of Branded Drug Industry  
1.8.1 Prosperity of the Branded Drug Industry  
1.8.2 Lack of Innovation  
1.8.3 Marketing Spend and Tactics  
1.8.4 Safety Issues  
1.8.5 Keeping Generics Off the Market  
1.9 Diversification  

**2. The Life Cycle of Industries, Technologies, and Brands**  

2.1 Diffusion of Innovations  
2.2 The Lifecycle Curve  
2.3 Lifecycle Phases  
2.3.1 Development Phase  
2.3.2 Introduction Phase  
2.3.3 Growth Phase  
2.3.4 Maturity Phase  
2.3.5 Decline Phase
3. The Life Cycle of a Pharmaceutical Brand

3.1 Lifecycle Curve of Pharmaceuticals
3.1.1 Slow Rate of Growth during the Growth Phase
3.1.2 Lack of a True Maturity Phase
3.1.3 Precipitous Decline Phase

3.2 Factors Affecting Rate of Conversion to Generics
3.2.1 Government Policy
3.2.2 Disease
3.2.3 Size of Brand
3.2.4 Hospital versus Nonhospital Drug Usage
3.2.5 Active Substance and Other Barriers to Entry

3.3 The Life Cycle of a Pharmaceutical Brand

PART B  LIFECYCLE MANAGEMENT REGULATORY AND LEGAL ENVIRONMENT

4. The Generic Approval Process
4.1 United States
4.2 Europe
4.3 Japan

5. Hatch-Waxman Legislation and Its Effects on LCM
5.1 Hatch-Waxman Act of 1984
5.2 Medicare Modernization Act of 2003
5.3 FDA Amendments Act of 2007
5.4 Q1 Program Supplemental Funding Act of 2008
5.5 Discussion of Hatch-Waxman Legislation

6. U.S. Health-Care Reform 2010

7. European Sector Inquiry

PART C  PATENTS AND EXCLUSIVITIES

8. Patents and Other Intellectual Property Rights
8.1 Nonpatent Intellectual Property Rights
8.2 What Are Patents?
8.3 What Is Patentable?
8.3.1 Patentable Subject Matter
8.3.2 Novelty
8.3.3 Inventive Step 85
8.3.4 Utility 86
8.3.5 Disclosure 86

8.4 How Long Does a Patent Last? 87
8.5 Patent Term Restoration in the United States 87
8.6 Supplementary Protection Certificates in Europe 88
8.7 Patent Term Extension in Japan 89
8.8 How Are Patents Obtained? 89
8.9 Patent Enforcement 91
8.10 Types of Patents 92
8.10.1 Composition of Matter Patent 93
8.10.2 Medical Use Patent 93
8.10.3 Formulation Patent 94
8.11 KSR versus Teleflex—Raising the Nonobviousness Bar 94
8.12 Patent Strategy 96

9. Nonpatent Exclusivities 99
9.1 NCE Exclusivity (United States) 99
9.2 New Clinical Study Exclusivity (United States) 100
9.3 Data and Marketing Exclusivity (Europe) 100
9.4 Data Exclusivity (Japan) 101
9.5 Orphan Drug Exclusivity 101
9.6 Pediatric Exclusivity 103
9.7 180-Day Generic Product Exclusivity 105


PART D DEVELOPMENTAL LCM 113

11. Strategic Principles of Developmental LCM 115
11.1 Developmental LCM Goal 1: Provide a Meaningful Improvement in Clinical Profile 116
11.2 Developmental LCM Goal 2: Increase the Potential Real-World Patient Potential for the Brand 118
11.3 Developmental LCM Goal 3: The Ability to Generate an ROI 120
11.4 Developmental LCM Goal 4: The Ability to Enhance Market Exclusivity of the Brand Franchise 121

12. Indication Expansion and Sequencing 123
12.1 Categories of Indication Expansion 123
# CONTENTS

13. Patient Subpopulations and Personalized Medicine 131
   13.2 Patient Selection without Predictive Criteria: Post Hoc Approaches 138
   13.3 What about the Patients Who Are Not Selected? 139

14. New Dosage Strengths, New Dosage Regimens 140
   14.1 New Dosage Strengths 140
   14.2 New Dosage Regimens 141

15. Reformulation, New Routes of Administration, and Drug Delivery 143
   15.1 Reformulation and New Routes of Administration 143
      15.1.1 Switch and Grow Strategy 143
      15.1.2 Expand and Grow Strategy 145
      15.1.3 Generic Defense 145
   15.2 Drug Delivery Devices 149

16. Fixed-Dose Combinations (FDCs) and Co-Packaging 152

17. Second-Generation Products and Modified Chemistry 159
   17.1 Isomerism 160
   17.2 Polymorphism 161
   17.3 Salts, Ethers, and Esters 162
   17.4 Prodrugs and Metabolites 163

18. Other Developmental LCM Strategies 165
   18.1 Manufacturing Strategies 165
   18.2 White Papers and Citizen Petitions 166

PART E COMMERCIAL LCM 167

19. Strategic Principles of Commercial LCM 169
   19.1 Commercial LCM Goal 1: The Ability to Drive Widespread and Preferential Patient Access to the Brand 170
   19.2 Commercial LCM Goal 2: The Ability to Defend Market Access and Formulary Position 170
   19.3 Commercial LCM Goal 3: The Ability to Optimize Profitability of the Brand Franchise 171
20. Geographical Expansion and Optimization 172
  20.1 Geographic Expansion 174
  20.2 Harmonization and Rationalization 175

21. OTC Switching 178
  21.1 What to Switch: Choosing the Best Approach 179
  21.2 Where to Switch: Dealing with Intermarket Variability 181
  21.3 When to Switch: Balancing the Product Life Cycle? 183
  21.4 How to Make the Switch Successful: What Corporate Support Is Required? 184

22. Brand Loyalty and Service Programs 186

23. Strategic Pricing Strategies 190
  23.1 Pricing Strategy and Tactics in the Launch and Growth Phases 190
  23.2 Pricing Strategy and Tactics Following Patent Expiry 193

24. Generic Strategies and Tactics 198

  Building a Generic Portfolio: Old versus New Thinking 202

25. Exit Strategies 204

  Executing the Exit Strategy 206

PART F BIOLOGICS AND BIOSIMILARS 207

26. Biologics and LCM 209
  26.1 Emergence of Biotech 209
  26.2 Some Definitions 210
    26.2.1 Biologics 210
  26.3 Uptake and Value of Biologics 211
  26.4 LCM of Biologics 213
    26.4.1 Next-Generation Biologics 213
    26.4.2 Reformulation 214
    26.4.3 Indication Expansion 215
    26.4.4 Self-Injection Devices 215

27. Biosimilars and Their Impact on Biologic LCM 217
  27.1 Changing Terminology: Biogenerics, Biosimilars, and FOBs 217
  27.2 Why Are Biosimilars a Big Deal? 219
27.3 How Are Biosimilars Different? 220
27.4 Biosimilar Approval Pathways 220
  27.4.1 Biosimilars in Europe 220
  27.4.2 Biosimilars in the United States 221
  27.4.3 Biosimilars around the World 222
27.5 Substitution of Biosimilars 223
  27.5.1 Automatic Substitution 223
  27.5.2 Therapeutic Substitution 224
27.6 Innovator Responses to Biosimilar Threats 225
27.7 The Future for Biologics LCM 226
  27.7.1 Legal Strategies in the United States 227
  27.7.2 Indication Expansion in Europe 228
  27.7.3 Brand Loyalty Programs and Services 229
27.8 The Emergence of the “Innovasimilar” Biopharma Company 229
27.9 Final Words 231

PART G THE INTEGRATED BRAND LCM STRATEGY AND ITS IMPLEMENTATION 233

28. Strategic Goals of LCM Brand Plans 235
  28.1 Position to Market 235
  28.2 Comparative Clinical Profile versus Gold Standard 237
  28.3 Level of Market Unmet Need 237

29. Ten Keys to Successful LCM 238
  29.1 Excellent Functional Expertise 238
    29.1.1 Patent Attorneys 239
    29.1.2 Regulatory Affairs 240
    29.1.3 Clinical Development 240
    29.1.4 Formulation Scientists 241
    29.1.5 Marketing and Sales 242
    29.1.6 Manufacturing 243
  29.2 Visible Management Support 244
  29.3 Unambiguous Ownership 245
  29.4 An Early Start 246
  29.5 A Robust “Broad to Bespoke” Process 248
  29.6 Focus on “High LCM Value Brands” 249
  29.7 Adequate Resources 250
  29.8 Measurements and Rewards 250
  29.9 Training and Support 252
  29.10 Realism 252
30. Organizational Structures and Systems for Ensuring Successful LCM

30.1 Organization of Project and Brand Management
  30.1.1 Functional Structure
  30.1.2 Project Structure
  30.1.3 Matrix Structure

30.2 Project and Brand LCM Structures

30.3 LCM Center of Excellence

30.4 Composition of the LCM CoE

31. The LCM Process: Description, Timing, and Participants

31.1 Purpose of the LCM Process

31.2 Timing of the LCM Process

31.3 Description of the LCM Process

PART H INTEGRATING LCM WITH PORTFOLIO MANAGEMENT

32. Principles of Portfolio Management

33. LCM Projects in the Development Portfolio

34. Managing Established Brand Portfolios

  34.1 What Do You Do with a Priority Established Brand?
  34.2 What about the Nonpriority Brands?
  34.3 Building the Ideal Established Brands Portfolio

CONCLUSIONS

APPENDIX: CASE HISTORIES

A.1 Market and Product-Shaping Dynamics in Action
  Alzheimer's Disease Therapies: Aricept®, Exelon®, and Reminyl®/Razadyne®
  Learnings

A.2 Optimizing Clinical Profile versus Gold Standards
  Angiotensin II Receptor Blockers (ARBs): Cozaar®, Micardis®, and Benicar®
  Learnings
A.3 Partnering to Ensure Reimbursement and Collection of Cost-Effectiveness Data 299
  Aricept  299
  Learnings  301

A.4 Active Metabolites and Late-Listed Patents 301
  Buspar®  301
  Learnings  303

A.5 A Fixed-Dose Combination (FDC) That Could Not Fail, or Could It? 303
  Caduet®  303
  Learnings  304

A.6 Indication Expansion 305
  Certican®/Zortress® and Afinitor® 305
  Learnings  306

A.7 Killing a Franchise through Over-the-Counter (OTC) Switching 307
  Claritin®  307
  Learnings  308

A.8 Moving FDCs to the Fore in Diabetes 308
  Diabetes Therapies: Glucophage®, Avandia®, Actos®, and Januvia® 308
  Learnings  310

A.9 FDCs and Multiple Dosage Strengths 310
  Diovan® and Tekturna®/Rasilez® 310
  Learnings  312

A.10 Building a Compliance Support Program 312
  Enbrel®  312
  Learnings  314

A.11 Targeting Responders with High-Price Cancer Agents 314
  Erbitux®  314
  Learnings  315

A.12 Failure of a “No-Brainer” LCM Strategy 315
  Exubera®  315
  Learnings  319

A.13 At-Risk Launches and Prodrug Patents 320
  Famvir®  320
  Learnings  321

A.14 New Dosages, FDC, and Patent Litigation 322
  Fosamax®  322
  Learnings  324
A.15 High Regulatory Hurdles for Lifestyle Drugs  
   Girosa®  
   Learnings  
A.16 Big Money from Orphan Indications  
   Gleevec®  
   Learnings  
A.17 Not Giving Up on a Controversial Brand  
   Iressa®  
   Learnings  
A.18 Expanding a Medical Aesthetics Franchise with an Ophthalmic Drug  
   Latisse®  
   Learnings  
A.19 Patent Expiry of the Biggest Drug Brand Ever  
   Lipitor®  
   Learnings  
A.20 Early Out-Licensing by Biotech: Take the Money and Run  
   Macugen®  
   Learnings  
A.21 Codevelopment and Comarketing Deals End in a Megamerger  
   Merck and Schering-Plough: Zetia®/Vytorin® and Claritin/Singulair®  
   Zetia/Vytorin  
   Claritin/Singulair  
   Learnings  
A.22 A Hugely Successful LLCM Switch Strategy: Business Needs and Reputational Issues Collide  
   Prilosec® and Nexium  
   The Facts  
   The Public Reaction  
   Learnings  
A.23 Combining Production Outsourcing with Settlement with a Generic Competitor  
   Nexium  
   Learnings  
A.24 Reformulating for Success in Osteoporosis  
   Osteoporosis Drugs: Fosamax, Actonel®, Boniva®, and Aclasta®  
   Learnings
A.25 Isomerism, Polymorphism, and Settlements 354
   Plavix® 354
   *Learnings* 355
A.26 Payers versus Brand for Patient Selection 356
   Plavix and Brilinta 356
   *Learnings* 357
A.27 Litigation Can Delay Generic Entry in the OTC Field Too 358
   Prilosec OTC 358
   *Learnings* 359
A.28 Inconsistent Court Decisions Can Hurt Both Brand and Generic Companies 360
   Protonix® 360
   *Learnings* 361
A.29 Holding on to an Antipsychotic Franchise 362
   Risperdal®/Invega® 362
   *Learnings* 363
A.30 LCM Creates an Almost Immortal Brand 364
   Voltaren® 364
   *Learnings* 365
A.31 LCM of a Women’s Health Franchise 366
   The Yasmin® Family 366
   *Learnings* 368
A.32 Indication Expansion/New Dosage Strength 369
   Zometa/Reclast® (Aclasta) 369
   *Learnings* 370

INDEX 371